

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

ATTENDS HEALTHCARE PRODUCTS, INC.
Petitioner,

v.

PAUL HARTMANN AG
Patent Owner.

Case IPR2020-01479
Patent No. 8,771,249

JOINT MOTION TO TERMINATE PROCEEDING

Pursuant to 35 U.S.C. § 317(a) and 37 C.F.R. § 42.72, Petitioner Attends Healthcare Products, Inc. (“Attends”) and Patent Owner PAUL HARTMANN AG (“HARTMANN”) jointly request termination of the *Inter Partes* Review of U.S. Patent No. 8,771,249, Case No. IPR2020-01479.

Petitioner and Patent Owner have reached an agreement resolving the dispute in the above-captioned *inter partes* review. The Board issued a Final Written Decision on February 22, 2022. Patent Owner appealed that decision, and the United States Court of Appeals for the Federal Circuit vacated the Final Written Decision on March 4, 2024, and remanded the proceeding to the Board. The proceeding is currently pending on remand from the Board. The Board has not issued any Final Written Decision after remand.

In an email dated June 18, 2024, the Board authorized the parties to file a joint motion to terminate and a request to treat the settlement agreement as business confidential information pursuant to 37 C.F.R. § 42.74.(c). In accordance with 35 U.S.C. § 317(b) and 37 C.F.R. § 42.74(b), a true copy of the Settlement and License Agreement between Attends Healthcare Products, Inc. on the one hand and PAUL HARTMANN AG on the other hand made in connection with, or in contemplation of, the termination of this proceeding is included with this request. True copies of the other agreements referenced in the Settlement and License Agreement, are also included with this request. Attends and HARTMANN confirm

that there are no other agreements (other than those filed with the Board), oral or written, between the parties made in connection with, or in contemplation of, the termination of this proceeding.

Petitioner and Patent Owner hereby request that the Agreements filed herewith as Exhibits 2008, 2009, and 2010 be treated as business confidential information, be kept separate from the file of the involved patents, and be made available only to Federal Government agencies on written request, or to any person on a showing of good cause pursuant to 35 U.S.C. § 317(b) and 37 C.F.R. § 42.74(c). A joint request to keep these agreements as Business Confidential Information Pursuant to 35 U.S.C. § 317(b) is being concurrently filed herewith.

Respectfully submitted,

Dated: September 25, 2024

/Eagle H. Robinson/
Eagle H. Robinson, Reg. No. 61,361
Counsel for Petitioner Attends Healthcare
Products, Inc.

Dated: September 25, 2024

/Joshua L. Goldberg/
Joshua L. Goldberg, Reg. No. 59,369
Counsel for Patent Owner PAUL
HARTMANN AG

CERTIFICATE OF SERVICE

The undersigned hereby certifies that a copy of the foregoing **Joint Motion to Terminate Proceeding** was served on September 25, 2024, via email directed to counsel of record for the Petitioner at the following:

Eagle H. Robinson
Michael J. Pohl
Jeremy B. Albright
NORTON ROSE FULBRIGHT US LLP
98 San Jacinto Boulevard, Suite 1100
Austin, TX 78701
eagle.robinson@nortonrosefulbright.com
michael.pohl@nortonrosefulbright.com
jeremy.albright@nortonrosefulbright.com

Petitioner has consented to service by electronic mail.

Dated: September 25, 2024

/William Esper/

William Esper
Legal Assistant and PTAB Coordinator
Finnegan, Henderson, Farabow,
Garrett & Dunner, LLP